

Centers for Disease Control and Prevention National Institute for Occupational Safety and Health 1090 Tusculum Avenue Cincinnati OH 45226-1998

April 9, 2015

The Health Council of the Netherlands
Subcommittee on the Classification of Reproduction Toxic Substances
Attn: P.W. van Vliet, Ph.D.
PO Box 16052
2500 BB The Hague
the Netherlands

Dear Dr. van Vliet:

Thank you for the opportunity to review the draft report on *Cytarabine* prepared by the Subcommittee on the Classification of Reproduction Toxic Substances of the Dutch Expert Committee on Occupational Safety (DECOS). Comments are enclosed that were prepared by Jane Ma, Research Chemist, NIOSH/Health Effects Laboratory Division (HELD), 1095 Willowdale Rd., Morgantown, WV 26505-2888.

If you have any questions regarding the comments, please contact me at 513-533-8260 (telephone) or by Email at tbl7@cdc.gov.

Sincerely yours,

Thomas J. Lentz, Ph.D., M.P.H.

Branch Chief

Document Development Branch Education and Information Division

1 Enclosure

Peer Review Comments on DECOS draft document Cytarabine by Jane Ma, Research Chemist, NIOSH/Health Effects Laboratory Division (HELD), 1095 Willowdale Road, Morgantown, WV 26505

SECTION & PARAGRAPH	COMMENT
General Comments	The document presented a detailed review on the available data on human and animal studies and provided pertinent conclusions, based on the evaluation of the data concerning the adverse effects of cytarabine treatment on reproductive toxicity. The document is presented in sufficient detail to support the conclusions, the presentation is sufficiently concise and included all critical studies; and based on data presented, there are no alternative interpretations to the overall assessment of the reproductive risks.
Specific Comments	This document was prepared in November, 2014. At the present time, there is a paper by Chang, A. and Patel, S.entitled "Treatment of acute myeloid leukemia during pregnancy" (http://aop.sagepub.com/content/49/1/48.full.pdf+html). This review article provides a systematic literature search of Pubmed from January 1969 to June 2014, which included studies on eighty-five fetuses exposed to cytarabine alone or with other chemotherapeutic agents administered to the mothers under chemotherapy at different stages of their pregnancy. This would be a very good reference for the document, if the Committee chooses to update it.